-
Morepen Bags Rs. 825 Crore Global Deal
Morepen Laboratories Limited (NSE: MOREPENLAB; BSE: 500288) has secured a multi-year Contract Development and Manufacturing Organization (CDMO) mandate valued at approximately Rs. 825 crore (USD 91 million) from a leading global pharma major. Morepen Bags Rs. 825 Crore Global Deal, Expands into High-Growth CDMO Segment Supplies under the mandate are expected to commence within the…
-
Akums Delivers Strong Q3 FY26 Performance with 14.8% Revenue Growth and 21% Adj EBITDA Growth
New Delhi, Delhi, India Akums Drugs & Pharmaceuticals Ltd., India’s Largest Contract Development and Manufacturing Organizations (CDMO), announced its financial results for the third quarter of FY26. Q3 FY 26 saw strong performance across its key business segments. CDMO saw a revenue growth of over 16% spurred on by double digit increase in volumes. The…
-
Jersey College Offers Associate Degree for NJ Nursing Students With and Without Prior Licensure
Teterboro and Ewing campuses offer full ADN program. Next class starts August 17. June 02, 2026 10:05 ET | Source: Jersey College TETERBORO, N.J., June 02, 2026 (GLOBE NEWSWIRE) — Jersey College, the institution dedicated to excellence in nursing education, provides an Associate Degree in Nursing program at its Teterboro and Ewing, N.J., campuses, offering…
-
MAPS Publishes First-of-Its-Kind Literature Review on Psychedelic Healing for People Impacted by the Criminal Legal System
“Relocating the Root” is a scoping literature review on the mental health needs of people directly impacted by the criminal legal system Publishing this literature review launches a project that builds on nearly four decades of MAPS advocacy by turning the lens of psychedelic research toward people directly harmed by the war on drugs MAPS…
-
Pictor® Reports Strong Commercial Momentum One Year After Launching U.S. Headquarters
The targeted proteomic platform company marks its first anniversary in Carlsbad with four commercial partnerships, seven products, BSL-2 equipped lab, and growing adoption across human and animal health markets globally CARLSBAD, Calif., June 2, 2026 /PRNewswire/ — As laboratories increasingly seek faster, more cost-efficient alternatives to legacy single-analyte testing, demand for scalable multi-analyte proteomic workflows is…
-
Raay Neo Pharma Launches to Transform India's Healthcare Landscape with Quality-Driven, Patient-Centric Pharmaceutical Solutions
Mumbai, Maharashtra, India Raay Neo Pharma, a next-generation pharmaceutical company, has officially unveiled its operations with the aim to contribute to quality healthcare for all Indians. Founded using a flexible and scalable operational framework and supported by more than five decades of diverse entrepreneurial success, Raay Neo Pharma will be introducing its range of more…
-
Morepen Labs' Facility Clears USFDA Inspection with NIL Adverse Observation for the Record Fourth Consecutive Time
Company sets a benchmark again in pharmaceutical excellence reinforcing its global leadership in quality and regulatory compliance Gurugram, Haryana, India Morepen Laboratories Limited (NSE: MOREPENLAB; BSE: 500288) has announced the successful completion of a USFDA (United States Food and Drug Administration) inspection at its Masulakhanna (Himachal) facility, with Zero adverse observations (No Form 483 issued…
-
J-Star Holding Provides Additional Details on Baytown Economic Development Foundation LOI Supporting Proposed U.S. Solid-State Battery Manufacturing Facility
Formal LOI Details Site Selection Support, Infrastructure Requirements, 18-Month Site Availability Commitment, and Framework for Long-Term Facility Development June 01, 2026 11:50 ET | Source: J-Star Holding Co., Ltd TAICHUNG CITY, Taiwan, June 01, 2026 (GLOBE NEWSWIRE) — J-Star Holding Co., Ltd. (Nasdaq: YMAT) (“J-Star” or the “Company”), today provided additional details regarding the commitment…
-
Zealand Pharma – Transactions related to share buy-back program (week 22, 2026)
Company announcement No. 20 / 2026 Zealand Pharma – Transactions related to share buy-back program (week 22, 2026) Copenhagen, Denmark, June 1, 2026 – Zealand Pharma A/S (“the Company” or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today reports transactions related to its share buy-back program (the…
-
Servier to Acquire Edgewise Therapeutics’ Muscular Dystrophy Business
Acquisition supports Servier’s strategic ambition in rare neurology for patients with high unmet medical needs. Transaction includes sevasemten, a late-stage investigational treatment for Becker and Duchenne muscular dystrophies. Transaction represents total value of up to $2.65 billion. SURESNES, France, June 1, 2026 /PRNewswire/ — Servier, an independent international pharmaceutical group governed by a foundation, today announced that…
-
Platinum Industries Announces Entry into Life Sciences; Collaborates with Dr. Abhigyan Upadhyay to Lead the New Enterprise, Rivadu Lifesciences Pvt. Ltd.
Strengthens leadership to build a research-driven and globally scalable model in high-value life sciences segments Mumbai, Maharashtra, India Platinum Industries Ltd. [NSE: PLATIND; BSE: 544134], an innovation-driven specialty chemicals company announced its strategic entry into the life sciences sector, marking a significant step in its next phase of growth. As part of this expansion, the…
-
Akums Reports Q4 FY26 and Full Year FY26 Results with Healthy Top Line and Strong EBITDA Growth; Board Recommends Dividend
New Delhi, Delhi, India Akums Drugs & Pharmaceuticals Ltd., India’s largest Contract Development and Manufacturing Organisation (CDMO), announced its financial results for the fourth quarter and the full year ended March 31, 2026. The company delivered a steady performance during Q4 FY26, with healthy revenue growth and improved operating profitability driven by its core domestic…
-
Johnson & Johnson’s Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, versus hormone therapy alone, potentially shifting a decades-long treatment paradigm
Compared with patients receiving hormone therapy alone, patients were nine times more likely to have little to no cancer remaining in the prostate after surgery, with a 20 percent reduction in the risk of developing metastasis or death1 Data selected to open the plenary presentation at ASCO 2026 and published in The New England Journal…
-
Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
REDWOOD CITY, Calif., May 31, 2026 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced detailed results from the global, randomized Phase 3 RASolute 302 clinical trial evaluating daraxonrasib, an oral RAS(ON) multi-selective inhibitor, in patients with previously treated metastatic pancreatic…
-
Niche Group Advances India's Vision Across Organic Farming and Cancer Treatment
At the same time, he revealed that Niche Agriculture and Pharmaceuticals Limited (NAPL) is working on affordable medicines for diseases such as cancer, epilepsy, and Alzheimer’s. Hundreds of PhD scholars were also interviewed and selected for opportunities during the event. Nestled amidst the beauty of nature, the auditorium of CSKHPKV transformed into far more than…
-
Morepen Labs Q4 Net Profit Rises 69 percent; CDMO Program Moves into Commercial Execution; Board Proposes a Dividend of 10 percent for FY 2025-26
Gurugram, Haryana, India Morepen Laboratories Limited reported strong Q4 FY26 performance with net profit rising 69% YoY to Rs. 20 crore and gross revenue increasing 22% YoY to Rs. 472 crore. Revenue growth during the quarter was supported by export momentum and expansion in the Medical Devices business, while operational momentum strengthened toward the latter…
-
Precede Biosciences Presents New ASCO 2026 Data Demonstrating Ability of Precede Bio Insight™ to Decode MET-Driven Biology and Resistance in Advanced NSCLC
Data include assessment of MET expression, tumor and immune pathway activity, and lineage plasticity from just 1 mL of plasma in advanced NSCLC Plasma MET test showed high concordance with tissue IHC/FISH in EGFR-mutated NSCLC following progression on first-line targeted therapy (AUC=0.97) Baseline and longitudinal profiling in METex14 skipping NSCLC identified biology associated with therapeutic…
-
Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer
IMA401 achieved deep and durable responses in various indications, including melanoma and head and neck cancer, with an initial promising clinical signal observed in lung cancer In head and neck cancer, IMA401 treatment at recommended Phase 2 dose (RP2D) with or without pembrolizumab resulted in a 29% confirmed ORR (4/14), 64% DCR (9/14) and mDOR…
-
World MS Day: National Policy Dialogue Adopts Landmark 10-Point Declaration Calling for Stronger Recognition of Invisible Disabilities in India
~Stakeholders urge reforms across disability certification, healthcare access, insurance, workplace inclusion and national health systems to improve outcomes for people living with Multiple Sclerosis and other invisible neurological conditions~ NEW DELHI, May 30, 2026 /PRNewswire/ — In a significant step towards strengthening disability-inclusive healthcare and social protection in India, Members of Parliament, policymakers, neurologists, disability…
Latest News
About the Author
We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.
